|
1
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics, 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar
|
|
2
|
De Marzo AM, Platz EA, Sutcliffe S, et al:
Inflammation in prostate carcinogenesis. Nat Rev Cancer. 7:256–269.
2007.
|
|
3
|
Pienta KJ and Smith DC: Advances in
prostate cancer chemotherapy: a new era begins. CA Cancer J Clin.
55:300–318. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maluf FC, Smaletz O and Herchenhorn D:
Castration-resistant prostate cancer: systemic therapy in 2012.
Clinics. 67:389–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenberg JE, Weinberg VK, Kelly WK, et
al: Activity of second-line chemotherapy in docetaxel-refractory
hormone-refractory prostate cancer patients. Cancer. 110:556–563.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miller R, Gerster J, Owens M, Slade H and
Tomai M: Review article imiquimod applied topically: a novel immune
response modifier and new class of drug. Int J Immunopharmacol.
21:1–14. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Von Krogh G, Lacey C, Gross G, Barrasso R
and Schneider A: European course on HPV associated pathology:
guidelines for primary care physicians for the diagnosis and
management of anogenital warts. Sex Transm Infect. 76:162–168.
2000.PubMed/NCBI
|
|
9
|
Sidky YA, Borden EC, Weeks CE, Reiter MJ,
Hatcher JF and Bryan GT: Inhibition of murine tumor growth by an
interferon-inducing imidazoquinolinamine. Cancer Res. 52:3528–3533.
1992.PubMed/NCBI
|
|
10
|
Hengge UR, Roth S and Tannapfel A: Topical
imiquimod to treat recurrent breast cancer. Breast Cancer Res
Treat. 94:93–94. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beutner KR, Geisse JK, Helman D, Fox TL,
Ginkeld A and Owens ML: Therapeutic response of basal cell
carcinoma to the immune response modifier imiquimod 5% cream. J Am
Acad Dermatol. 41:1002–1007. 1999.
|
|
12
|
Schön M, Bong AB, Drewniok C, et al:
Tumor-selective induction of apoptosis and the small-molecule
immune response modifier imiquimod. J Natl Cancer Inst.
95:1138–1149. 2003.PubMed/NCBI
|
|
13
|
Schön MP, Wienrich BG, Drewniok C, et al:
Death receptor-independent apoptosis in malignant melanoma induced
by the small-molecule immune response modifier imiquimod. J Invest
Dermatol. 122:1266–1276. 2004.PubMed/NCBI
|
|
14
|
Berman B, Sullivan T, De Araujo T and
Nadji M: Expression of Fas-receptor on basal cell carcinomas after
treatment with imiquimod 5% cream or vehicle. Br J Dermatol.
149:59–61. 2003.
|
|
15
|
Smith KJ, Germain M and Skelton H:
Squamous cell carcinoma in situ (Bowen’s disease) in renal
transplant patients treated with 5% imiquimod and 5% 5-fluorouracil
therapy. Dermatol Surg. 27:561–564. 2001.
|
|
16
|
Sullivan TP, Dearaujo T, Vincek V and
Berman B: Evaluation of superficial basal cell carcinomas after
treatment with imiquimod 5% cream or vehicle for apoptosis and
lymphocyte phenotyping. Dermatol Surg. 29:1181–1186. 2003.
|
|
17
|
Smith EB, Schwartz M, Kawamoto H, et al:
Antitumor effects of imidazoquinolines in urothelial cell carcinoma
of the bladder. J Urol. 177:2347–2351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schwartz MJ, Liu H, Hwang DH, Kawamoto H
and Scherr DS: Antitumor effects of an imidazoquinoline in renal
cell carcinoma. Urology. 73:1156–1162. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hayashi T, Crain B, Corr M, et al:
Intravesical Toll-like receptor 7 agonist R-837: optimization of
its formulation in an orthotopic mouse model of bladder cancer. Int
J Urol. 17:483–490. 2010. View Article : Google Scholar
|
|
20
|
Asakura M and Miura H: Imiquimod 5% cream
for the treatment of nasal lesion of metastatic renal cell
carcinoma. Dermatol Ther. 24:375–377. 2011.
|
|
21
|
Liu H, Schwartz MJ, Hwang DH and Scherr
DS: Tumour growth inhibition by an imidazoquinoline is associated
with c-Myc down-regulation in urothelial cell carcinoma. BJU Int.
101:894–901. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kauffman EC, Liu H, Schwartz MJ and Scherr
DS: Toll-like receptor 7 agonist therapy with imidazoquinoline
enhances cancer cell death and increases lymphocytic infiltration
and proinflammatory cytokine production in established tumors of a
renal cell carcinoma mouse model. J Oncol. 2012:1032982012.
View Article : Google Scholar
|
|
23
|
Foster BA, Gingrich JR, Kwon ED, Madias C
and Greenberg NM: Characterization of prostatic epithelial cell
lines derived from transgenic adenocarcinoma of the mouse prostate
(TRAMP) model. Cancer Res. 57:33251997.PubMed/NCBI
|
|
24
|
Touny LH and Banerjee PP: Identification
of both Myt 1 and Wee 1 as necessary mediators of the p21
independent inactivation of the cdc 2/cyclin B1 complex and growth
inhibition of TRAMP cancer cells by genistein. Prostate.
66:1542–1555. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Toyoshima F, Moriguchi T, Wada A, Fukuda M
and Nishida E: Nuclear export of cyclin B1 and its possible role in
the DNA damage-induced G2 checkpoint. EMBO J. 17:2728–2735. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
O’Connor PM: Mammalian G1 and G2 phase
checkpoints. Cancer Surv. 29:151–182. 1997.
|
|
27
|
Sainathan SK, Bishnupuri KS, Aden K, et
al: Toll-like receptor-7 ligand imiquimod induces type I interferon
and antimicrobial peptides to ameliorate dextran sodium
sulfate-induced acute colitis. Inflamm Bowel Dis. 18:955–967. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schon MP, Schon M and Klotz KN: The small
antitumoral immune response modifier imiquimod interacts with
adenosine receptor signaling in a TLR7-and TLR8-independent
fashion. J Invest Dermatol. 126:1338–1347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Drobits B, Holcmann M, Amberg N, et al:
Imiquimod clears tumors in mice independent of adaptive immunity by
converting pDCs into tumor-killing effector cells. J Clin Invest.
122:575–585. 2012. View
Article : Google Scholar
|
|
30
|
Hartwell LH and Kastan MB: Cell cycle
control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moarbess G, El-Hajj H, Kfoury Y, et al:
EAPB0203, a member of the imidazoquinoxaline family, inhibits
growth and induces caspase-dependent apoptosis in T-cell lymphomas
and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood.
111:3770–3777. 2008. View Article : Google Scholar
|
|
32
|
Zagon IS, Donahue RN, Rogosnitzky M and
Mclaughlin PJ: Imiquimod upregulates the opioid growth factor
receptor to inhibit cell proliferation independent of immune
function. Exp Biol Med (Maywood). 233:968–979. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiarini F, Grimaldi C, Ricci F, et al:
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian
target of rapamycin inhibitor NVP-BEZ235 against T-cell acute
lymphoblastic leukemia. Cancer Res. 70:8097–8107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meyer T, Nindl I, Schmook T, Ulrich C,
Sterry W and Stockfleth E: Induction of apoptosis by Toll-like
receptor-7 agonist in tissue cultures. Br J Dermatol. 149:9–13.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cryns V and Yuan J: Proteases to die for.
Genes and development. 12:1551–1570. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Imbertson LM, Beaurline JM, Couture AM, et
al: Cytokine induction in hairless mouse and rat skin after topical
application of the immune response modifiers imiquimod and S-28463.
J Invest Dermatol. 110:734–739. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rechtsteiner G, Warger T, Osterloh P,
Schild H and Radsak MP: Cutting edge: priming of CTL by
transcutaneous peptide immunization with imiquimod. J Immunol.
174:2476–2480. 2005. View Article : Google Scholar : PubMed/NCBI
|
